Skip to main content

On-Demand, Wearable Insulin with

CeQur Simplicity on Your Side

Convenient

One click delivers 2 units of rapid-acting insulin.

Discreet

Compact, lightweight, and easily hidden under your clothes.1

Injection-Free

Soft cannula, no pain, no hassle.1

Get CeQur Simplicity Today

CeQur Simplicity™ CliQuers have declared their independence. They’ve taken control of their blood sugar and found freedom from multiple daily injections, with the effortless, wearable patch for mealtime insulin. Just fill out this simple form to have our CeQur Care team
contact you.

This testimonial represents the experience of this particular patient. Patients’ experience may vary. CeQur Simplicity has been studied for use in adults over the age of 21 who have been diagnosed with diabetes. The system is not intended for use in pediatric patients.






    * Indicates required fields

    Select an option*


    * Indicates required fields

    We respect the importance of your privacy and understand your health is a very personal and sensitive subject. CeQur Simplicity wants you to understand how it will use the information provided by you on this registration page. By clicking the “Submit” button above, you are indicating that CeQur Simplicity or its partners may use your information for program improvements, quality monitoring, data and analytics for commercial purposes, and future marketing communications. You also understand that you may opt out from receiving any future communications from CeQur Simplicity or its partners by clicking the “unsubscribe” link within any email you receive, or by calling 1-888-552-3787.

    To better understand how CeQur Simplicity values your privacy, please see our Privacy Policy.

    CeQur Simplicity is a revolutionary patch that delivers injection-free mealtime insulin.​ It’s not a pen. It’s not a pump. It’s a wearable insulin patch!

    Using a tiny, flexible cannula, you can deliver rapid-acting insulin under your skin. It changes the way you dose for meals and correction boluses, eliminating the need for multiple daily injections.

    References
    1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
    2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1).
    3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
    4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
    5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
    6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603.
    7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.
    8. 2020 HEDIS Measures summary of changes. HEDIS Measures and Technical Resources 2020  [cited 2020 March 9]; available from: https://www.ncqa.org/hedis/measures/comprehensive-diabetes-care/.
    9. Peyrot M, et al. Correlates of insulin injection omission. Diabetes Care. 2010; 33(2): p. 242-243 charts, discussion p. 244.

    10. Barry R, Johns DON, Rees B. 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. Diabetes, 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on Bergenstal Trial.

    11. Results from standardized dQ&A patient survey. Data on file at CeQur.